Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen

Revenues up 11% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen

2Q Revenues: $5.2 billion (+11%)

2Q Earnings: $1.5 billion (+26%)

YTD Revenues: $9.7 billion (+9%)

YTD Earnings: $2.6 billion (-35%)

Comments: Enbrel sales increased 7% to $1.2 billion in the quarter. Kyprolis sales were $78 million (acquired from Onyx Pharmaceuticals acquisision in 4Q13). Prolia sales increased 40% to $264 million. XGEVA sales increased 20% to $299 million, despite generic competition. Combined Neulasta (pegfilgrastim) and NEUPOGEN (filgrastim) sales declined 1% to $1.4 billion in the quarter. R&D expenses in the quarter were up 4% to $979 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters